In 2022, Tanyi and colleagues reported the results of a Phase I clinical investigation in which fourteen patients with mesothelin-positive solid tumors, inclusive of ovarian cancer, underwent treatment with mesothelin-redirected CAR-Ts harboring a humanized scFv as the targeting domain incorporated into a 4-1BB/CD3ζ-based CAR construct (154). This evidence concerns the gene CD247 and ovarian cancer.